Kimball Electronics Reports Q3 2026 Results: Sequential Growth, Medical Market Strength, and Guidance Affirmed

Key Highlights for Investors

• Q3 Revenue: \$352.9 million, representing a 3.4% sequential increase from Q2.
• Medical Vertical Outperformance: Sales in the medical market surged 10.2% quarter-on-quarter, highlighting robust demand and effective execution in a strategic growth area.
• Operating Margins: Adjusted operating margin for the quarter was 4.2%, with GAAP operating margin at 3.3%.
• Cash Generation: Kimball reported positive cash from operations for the ninth consecutive quarter, generating \$14.9 million in Q3.
• Share Repurchase: The company invested \$4.0 million to repurchase 165,000 shares in Q3, signaling management’s confidence in long-term value.
• Leverage and Liquidity: Debt stands at \$163.0 million, with \$276.0 million in borrowing capacity—the company remains well-capitalized.
• Cash Conversion Days: Improved to 90, down from 91 in Q2 and 99 in Q3 2025, reflecting enhanced working capital efficiency.
• Guidance Affirmed: The company reaffirmed its FY2026 guidance, with net sales expected in the \$1,400 – \$1,460 million range and adjusted operating income at the high end of 4.2% – 4.5% of net sales.
• Capital Expenditures: Expected to be \$50 – \$60 million for FY2026, supporting strategic investments in growth areas.

Strategic Insights and Shareholder-Relevant News

CEO Richard D. Phillips emphasized that Kimball’s medical Contract Manufacturing Organization (CMO) business remains a cornerstone of the company’s growth strategy. Kimball is making deliberate investments in capabilities, capacity, and commercial focus in this vertical, expecting it to materially boost both revenue and margins as volumes ramp up. Additionally, the company is exploring inorganic (acquisition-driven) growth to complement its organic strategy, which could be a powerful catalyst for future performance.

Vertical Market Performance

• Automotive: Q3 sales decreased 3% year-over-year; nine-month sales were down 9% compared to the prior year. Automotive remains the largest segment (46% of Q3 sales).
• Medical: Q3 sales declined 8% year-over-year due to a tough comparison (Q3 FY25 included a one-off \$24 million consigned inventory sale), but up 10.2% sequentially and up 5% year-to-date.
• Industrial (ex-AT&M): Q3 down 8% year-over-year; nine months down 5%.
• Automation, Test & Measurement (AT&M): Business divested as of July 31, 2024; no sales recorded in Q3 FY26.

Profitability and EPS Details

• Q3 Net Income: \$3.8 million (down from \$5.7 million in Q3 FY25).
• Adjusted Net Income: \$6.8 million in Q3 (down from \$8.0 million in Q3 FY25).
• Q3 Diluted EPS: \$0.15 (GAAP), \$0.27 (adjusted non-GAAP).
• Nine-Month EPS: \$0.41 (GAAP), \$0.79 (adjusted non-GAAP).

Balance Sheet and Cash Flow Strength

• Cash and Equivalents: \$82.5 million at March 31, 2026.
• Total Assets: \$1.10 billion.
• Share Owners’ Equity: \$577.6 million.
• Net Cash Provided by Operating Activities (YTD): \$29.8 million, though down from \$105.9 million in the prior-year period due to working capital investments and lower net income.
• Debt Profile: Current portion of long-term debt \$34.7 million; long-term debt \$127.9 million.

Other Notable Financial Metrics

• Depreciation and Amortization: \$10.3 million in Q3.
• Open Orders: \$602 million at March 31, 2026, providing visibility into future revenue streams.
• ROIC (Return on Invested Capital): 7.1% for the trailing twelve months, up from 6.1% in the prior year, showing improved capital efficiency.

Important Considerations for Shareholders

• Affirmation of Guidance: Kimball expects to finish FY2026 at the high end of its adjusted operating margin guidance, with solid sales outlook. This positive affirmation could support share price stability or appreciation.
• Medical CMO Focus and Inorganic Growth: The company’s heavy emphasis on expanding medical CMO capabilities and exploring M&A could drive future growth and valuation multiples.
• Share Repurchases: Ongoing buybacks indicate management confidence and may provide downside support to the share price.
• Balance Sheet Health: Ample liquidity and borrowing capacity may enable further strategic investments or acquisitions.
• Risks: Caution is warranted regarding macroeconomic conditions, geopolitical uncertainty, supply chain risks, and the ability to convert new business opportunities into revenue. Significant non-recurring items in prior periods may impact year-over-year comparability.

Conference Call and Further Information

Investors are invited to join the webcast on May 6, 2026, for more details and direct Q&A with management. An archived replay will be available on the company’s investor relations website.

Conclusion

Kimball Electronics’ Q3 2026 results demonstrate resilience, sequential growth, and prudent capital management. The continued success and investment in the medical CMO vertical, combined with disciplined execution and a robust balance sheet, support management’s confidence in meeting or exceeding full-year guidance. Shareholders should monitor ongoing strategic initiatives, particularly in medical and inorganic growth opportunities, as these may have a meaningful impact on future financial performance and share valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any securities. Investors should conduct their own due diligence and consult with their financial advisors before making any investment decisions. The information herein is based on company filings and may contain forward-looking statements subject to risks and uncertainties. Actual results may differ materially from those projected.

View Kimball Electronics, Inc. Historical chart here